Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SP2086

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for SP2086?

SP2086 is an investigational drug.

There have been 16 clinical trials for SP2086. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2013.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Renal Insufficiency. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd. and [disabled in preview].

There are four US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for SP2086
TitleSponsorPhase
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy VolunteersJiangsu HengRui Medicine Co., Ltd.Phase 1
The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes PatientsJiangsu HengRui Medicine Co., Ltd.Phase 1
The DDI Study of SP2086 and ValsartanJiangsu HengRui Medicine Co., Ltd.Phase 1

See all SP2086 clinical trials

Clinical Trial Summary for SP2086

Top disease conditions for SP2086
Top clinical trial sponsors for SP2086

See all SP2086 clinical trials

US Patents for SP2086

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SP2086   Start Trial Tetrahydro-imidazo[1,5-.alpha.]pyrazine derivatives, preparation process and medicinal use thereof Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co. Ltd. (Shanghai, CN)   Start Trial
SP2086   Start Trial Pharmaceutical composition for treatment of type 2 diabetes Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, CN)   Start Trial
SP2086   Start Trial Tetrahydro-imidazo[1,5-.alpha.] pyrazine derivatives, preparation process and medicinal use thereof Jiangsu Hengrui Medicine Co., Ltd. (Jiangsu, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Harvard Business School
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.